Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 7/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406659 | 0.85 | KMT2A (0.55) | FEN1CYP2C19ALDH1A1TSHRPDE4B | |
| SCHEMBL2407901 | 0.84 | PKM (0.52) | ALDH1A1TSHRPDE4BPOLBMAPK1 | |
| SCHEMBL4197958 | 0.82 | FEN1 (0.54) | FEN1CYP2C19ALDH1A1TSHRPDE4A | |
| SCHEMBL4194695 | 0.82 | PDE4B (0.47) | PDE4BPDE4DPOLBMAPK1MAPT | |
| SCHEMBL2415404 | 0.82 | PDE4B (0.47) | FEN1ALDH1A1TSHRPDE4BPDE4D | |
| SCHEMBL8691780 | 0.81 | ALDH1A1 (0.58) | FEN1CYP2C19ALDH1A1TSHRPDE4A | |
| SCHEMBL2412123 | 0.81 | PDE4A (0.57) | CYP2C19ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL15206969 | 0.80 | KDM4E (0.44) | FEN1ALDH1A1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL4185632 | 0.80 | PDE4B (0.48) | FEN1PDE4BPDE4DKMT2A | |
| SCHEMBL3514617 | 0.78 | FEN1 (0.47) | FEN1ALDH1A1LDHASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718821-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2817308-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-09-07 | — | — | EP | disclosed |
| CN-104271576-A | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC | 2015-01-07 | — | — | CN | disclosed |
| US-20130225589-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-1925617-B1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA PHARM CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-8193356-B2 | Heterocycle compound, and production process and application thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| EP-0232328-A1 | ZWITTERIONIC BICYCLIC COMPOUNDS AND THEIR SALTS, SOLVATES, HYDRATES AND ESTERS. | SCHERING CORP (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4684727-A | Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents | SCHERING CORPORATION (US) | 1987-08-04 | — | — | US | disclosed |
| WO-1987000752-A2 | ZWITTERIONIC BICYCLIC COMPOUNDS AND THEIR SALTS, SOLVATES, HYDRATES AND ESTERS | SCHERING CORPORATION (US) | 1987-02-12 | — | — | WO | disclosed |
| EP-0092786-B1 | 1,8-NAPHTHYRIDINE AND 1,5,8-AZANAPHTHYRIDINE DERIVATIVES | SCHERING CORPORATION (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4628055-A | ASTHMA, BRONCHITIS, 1,5,8-AZANAPHTHYRIDINES | SCHERING CORPORATION (US) | 1986-12-09 | — | — | US | disclosed |
| EP-0196024-A1 | Substituted 1,8-naphthyridinones, processes for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1986-10-01 | — | — | EP | disclosed |
| US-4596809-A | Substituted 1,8-naphthyridinones, useful as anti-allergic agents | SCHERING CORPORATION (US) | 1986-06-24 | — | — | US | disclosed |
| US-4551463-A | ANTIULCER | SCHERING CORPORATION (US) | 1985-11-05 | — | — | US | disclosed |
| US-4492702-A | ATIALLERGENS, LUNG DISEASES | SCHERING CORPORATION (US) | 1985-01-08 | — | — | US | disclosed |
| EP-0092786-A2 | 1,8-Naphthyridine and 1,5,8-azanaphthyridine derivatives | SCHERING CORPORATION (US) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225589-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | FEN1 870/4885CYP2C19 1229/4885ALDH1A1 1211/4885 |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | FEN1 1789/4885CYP2C19 347/4885ALDH1A1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.